Iftikhar Haissan, Awan Muhammad Ozair, Awan Muhammad Sohail, Mustafa Khawaja, Das Jai K, Ahmed Shahzada Khuram
Department of Otolaryngology, Rawal Institute of Health Sciences, Islamabad, Pakistan.
Department of Surgery, Aga Khan University Medical College, Karachi, Pakistan.
Int Arch Otorhinolaryngol. 2022 Jun 17;26(4):e744-e752. doi: 10.1055/s-0042-1749370. eCollection 2022 Oct.
Allergic rhinitis (AR) is estimated to affect up to 30% of the world population. With the rise in cases, newer treatment modalities have been explored. Probiotics have shown to reduce symptoms of AR and improve quality of life. A few systematic reviews have been published aiming to assess the role of probiotics in AR. To consolidate the recent evidence with an overview of systematic reviews by extracting data regarding subjective outcomes (from quality of life questionnaires, the Total Nasal Symptom Score, the Total Ocular Symptom Score, the Daily Total Symptom Score, the incidence of AR, and the Rhinitis Total Symptom Score) and objective outcomes (levels of antigen-specific immunoglobulin E [IgE], total IgE, interleukin 10 [IL-10], interferon gamma [IFNG], eosinophil, and the T helper 1/T helper 2 [Th1/Th2] ratio). We conducted a literature search on the PubMed, EBSCO CINAHL, EBSCO Dentistry & Oral Sciences Source, and Cochrane Library up to April 14, 2020. The qualitative assessment was performed using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR-2) tool. A total of 419 titles were screened, and 3 systematic reviews met our eligibility criteria. Probiotics in the treatment of AR have been shown to improve quality of life, the total nasal and ocular symptom scores, the daily total symptom scores and Th1/Th2 ratio. No difference was ascertained for rhinitis total symptom score, and the rates of antigen-specific IgE, total IgE, IL-10, INFG and eosinophil. The present review showed that there is considerable evidence that probiotics are useful in the treatment of AR. Further randomized trials targeting the limitations of the currently-available evidence can help ascertain the usefulness of probiotics in cases of AR.
据估计,变应性鼻炎(AR)影响着全球多达30%的人口。随着病例数的增加,人们探索了更新的治疗方式。益生菌已显示出可减轻AR症状并改善生活质量。已经发表了一些系统评价,旨在评估益生菌在AR中的作用。
为了通过提取关于主观结局(来自生活质量问卷、总鼻症状评分、总眼症状评分、每日总症状评分、AR发病率和鼻炎总症状评分)和客观结局(抗原特异性免疫球蛋白E [IgE]、总IgE、白细胞介素10 [IL-10]、干扰素γ [IFNG]、嗜酸性粒细胞以及辅助性T细胞1/辅助性T细胞2 [Th1/Th2] 比值水平)的数据,以系统评价概述的形式巩固近期证据。
我们在PubMed、EBSCO CINAHL、EBSCO牙科学与口腔科学资源库以及Cochrane图书馆进行了截至2020年4月14日的文献检索。使用系统评价方法学质量评估(AMSTAR-2)工具进行定性评估。共筛选了419个标题,3篇系统评价符合我们的纳入标准。益生菌治疗AR已显示可改善生活质量、总鼻和眼症状评分、每日总症状评分以及Th1/Th2比值。鼻炎总症状评分以及抗原特异性IgE、总IgE、IL-10、INFG和嗜酸性粒细胞的比率未发现差异。
本综述表明,有大量证据表明益生菌对AR治疗有用。针对现有证据局限性的进一步随机试验有助于确定益生菌在AR病例中的有用性。